Management to hold a conference call at 10:00 a.m. EST
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical
company dedicated to identifying, in-licensing and developing promising
therapeutic candidates, announced today that it will release its
unaudited financial results for the third quarter ended September 30,
2015 on Monday, November 16, 2015, before the U.S. markets open.
The Company will host a conference call on Monday, November 16, 2015 at
10:00 a.m. EST featuring remarks by Kinneret Savitsky, Ph.D., Chief
Executive Officer of BioLineRx, and Philip Serlin, Chief Financial and
Operating Officer of BioLineRx. The conference call will be available
via webcast and can be accessed through the Investor Relations section
of BioLineRx’s website, www.biolinerx.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast.
To dial into the conference call, please dial 1-888-668-9141 from the
U.S. or +972-3-918-0609 internationally. A replay of the conference call
will be available approximately two hours after completion of the live
conference call at www.biolinerx.com.
A dial-in replay of the call will be available until November 19, 2015;
please dial 1-888-254-7270 from the U.S. or +972-3-925-5928
internationally.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-8040, a cancer therapy platform,
which is in the midst of a Phase 2 study for relapsed/refractory acute
myeloid leukemia (AML), has recently initiated a Phase 2b study as an
AML consolidation treatment, and has successfully completed a Phase 1
study in stem cell mobilization; and BL-7010 for celiac disease, which
has successfully completed a Phase 1/2 study.
In December 2014, BioLineRx entered into a strategic collaboration
with Novartis for the co-development of selected Israeli-sourced novel
drug candidates. The companies intend to co-develop a number of
pre-clinical and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the “Risk Factors” section
of BioLineRx’s most recent annual report on Form 20-F filed with
the Securities and Exchange Commission on March 23, 2015. In addition,
any forward-looking statements represent BioLineRx’s views only as of
the date of this release and should not be relied upon as representing
its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by
law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151109005820/en/
Copyright Business Wire 2015